Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B
Top Cited Papers
Open Access
- 15 March 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (6), 687-696
- https://doi.org/10.1086/368083
Abstract
YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794Keywords
This publication has 40 references indexed in Scilit:
- Long-term mutation rates in the hepatitis B virus genomeMicrobiology, 2000
- Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with LamivudineThe Journal of Infectious Diseases, 1999
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Naturally Occurring Hepatitis B Virus Genomes Bearing the Hallmarks of Retroviral G → A HypermutationVirology, 1997
- Antiviral resistance: mechanisms, clinical significance, and future implicationsJournal of Antimicrobial Chemotherapy, 1996
- Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDSNew England Journal of Medicine, 1996
- A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse TranscriptaseNew England Journal of Medicine, 1993
- A Ganciclovir-Resistant Clinical Isolate of Human Cytomegalovirus Exhibiting Cross-Resistance to Other DNA Polymerase InhibitorsThe Journal of Infectious Diseases, 1992
- Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovirAntimicrobial Agents and Chemotherapy, 1991
- ISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPYThe Lancet, 1982